

AD _____

Award Number: W81XWH-04-1-0702

TITLE: Disruption of Brca2-Rad51 Complex in Breast Cancer Cells: Therapeutic Implications

PRINCIPAL INVESTIGATOR: Raquel S. Aloyz, Ph.D.

CONTRACTING ORGANIZATION: S. M. B. D. Jewish General Hospital
Montreal, Québec, Canada H3T 1E2

REPORT DATE: September 2006

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 01-09-2006		2. REPORT TYPE Final		3. DATES COVERED 1 Sep 2004 - 31 Aug 2006	
4. TITLE AND SUBTITLE Disruption of Brca2-Rad51 Complex in Breast Cancer Cells: Therapeutic Implications				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-04-1-0702	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Raquel S. Aloyz, Ph.D. E-mail: raloyz@hotmail.com				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) S. M. B. D. Jewish General Hospital Montreal, Québec, Canada H3T 1E2				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES Original contains colored plates: ALL DTIC reproductions will be in black and white					
14. ABSTRACT BRCA2-Rad51 interaction is required for the Rad51-related DNA repair pathway. Thus, inhibition of their interaction is expected to sensitize tumor cells to certain DNA damaging agents. A panel of 14080 natural compounds from the Chinese National Center for Drug Screening has been partially screened using a yeast two-hybrid system utilizing specific Rad51/BRCA2 constructs. Growth of the Rad51/BRCA2 yeast strain in different media lead us to the selection of 20 candidate inhibitors for BRAC2-Rad51 interaction. We are actually testing if these compounds sensitize breast cancer cell lines to cisplatin. One of the compounds at the concentrations attainable increases the toxicity of cisplatin in a BRCA1 deficient breast cancer cell line.					
15. SUBJECT TERMS Breast Cancer					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	11	19b. TELEPHONE NUMBER (include area code)

TABLE OF CONTENTS

A. SUMMARY OF THE PROJECT	-----Page 4
Background	
Rational	
Objective	
Strategy	
Biological Evaluation	
B. STATEMENT OF WORK (SOW)	-----Page 4
C. BODY of REPORT	-----Page 5
C.1 Task#1 Construction of the BRCA2-Rad51 Yeast 2 Hybrid System	-----Page5
C.2 Task#2 Screening of candidate Compounds to inhibit BRCA2-Rad51 Interaction	-----Page 6
C.2.1. Primary screening strategy	-----Page 6
C.2.2. Primary screening results	-----Page 7
C.2.3. Secondary screening strategy	-----Page 8
C.2.4. IC ₅₀ Value of candidate inhibitors	-----Page 8
C.3 Task#3 Biological Evaluation	-----Page 9
D. Key Research Accomplishments	-----Page 10
E. Reportable Outcomes	-----Page 11
F. CONCLUSION	-----Page 11
D. REFERENCES	-----Page 11

A. SUMMARY OF THE PROJECT

BACKGROUND

BRCA2 directly interacts with Rad51 promoting Rad51 directed DNA repair. Repair of interstrand crosslinks induced by interstrand crosslinking agents, involves the Rad51 related homologous recombinational repair pathway (HRR) (1). The homologous recombinational repair process requires the assembly of multienzymatic complexes visualized immunocytochemically as Rad51 nuclear foci. These complexes include the Rad51 paralogs family members such as (Rad51, Rad52, Rad54, Rad51B, Rad51C, Rad51D, Xrcc2 and Xrcc3) and the breast cancer associated proteins, BRCA1 and BRCA2. Defective cell lines in each of the above mentioned proteins present similar phenotypes: spontaneous chromosomal aberrations, high sensitivity to killing by cross-linking agents, mild sensitivity to gamma rays and attenuated Rad51 focus formation after exposure to ionizing radiation (2,3). Our innovative contribution will be to find natural compounds to sensitize tumor cells to chemotherapeutic agents by inhibiting BRCA2/Rad51 interaction.

RATIONALE

BRCA2 is central to HRR repair through BRC-mediated Rad51 interactions required for the assembly of DNA damage-induced RAD51 foci. Inhibition of their interaction would sensitize tumor cells to DNA crosslinking agents. Therefore our drug discovery program focus on the identification of compounds capable of competitively block the interaction BRCA2 and Rad51 (3).

OBJECTIVE

Find natural compounds that will inhibit BRCA2-Rad51 interaction in order to inhibit the homologous recombinational process and consequently sensitize breast tumor cells to therapeutic agents.

SELECTION of BRCA2-Rad51 CANDIDATE INHIBITORS

We have cloned the BRCA2 domain that interacts with Rad51 and full-length Rad51 and utilize these cDNA sequences to screen the panel of 15,000 natural compounds from the Chinese National Center for Drug Screening system using a yeast two hybrid system. We determine that 18 compounds displaying selective inhibition of BRCA2-Rad51 interaction had IC₅₀ values less than 10 µg/ml.

BIOLOGICAL EVALUATION of CANDIDATE INHIBITORS

The biological activity of selected compounds using the two yeast hybrid system was tested in a sporadic human breast cancer cell line panel (expressing wild type BRCA2) using the NCI sulforhodamine B assay (5). All tests were performed using sublethal doses of the selected compounds, in combination with cisplatin 0-40 µ of cisplatin. Drug interactions (antagonism, additive, or synergism) were assessed as described (6). The ability of to alter homologous recombinational repair will be examined immunocytochemically looking at changes on cisplatin-induced Rad51 foci in the presence of selected compounds. Disruption of Rad51-BRCA2 interaction will be confirmed by cross immunoprecipitation followed by western blot analysis using specific antibodies

B. ORIGINAL STATEMENT OF WORK

Task # 1 Construction of the BRCA2-Rad51 Yeast 2 Hybrid System
STATUS: COMPLETED (first year)

Task #2 Screening of candidate compounds to inhibit BRCA2-RAD51 interaction
STATUS: COMPLETED (first and second year)

Task #3 Biological Evaluation of candidate inhibitors of BRCA2-Rad51 interaction
STATUS: IN PROGRESS (second year)

C. BODY of REPORT

C.1. Task # 1 Construction of the BRCA2-Rad51 Yeast 2 Hybrid System

The BRCA2 domain which interacts with Rad51, was cloned from a human cDNA library using specific primers for human wild type BRCA2 (Accession Number NM_000059). The cDNA sequence corresponding to BRCA2 3196-3991 was amplified by PCR and subcloned into the pBTM116 vector in frame to LexA (BRCA2-LexA hereafter)(6).

The full length Rad51 was cloned from a human cDNA library using specific primers for human wild type Rad51 (Accession Number NM_002875). The Rad51 full cDNA was amplified by PCR and subcloned into the plasmid PACT2 vector in frame to GAL4-TA (GALA4-TA-Rad51 hereafter)(7).

We confirm the proper orientation of the inserts and sequence by agarose electrophoresis after restriction endonuclease digestion and sequencing respectively.

The vectors were transformed either alone or together into the yeast strain L40 (*MATa trp1 leu2 his3 LYS2::lexA-HIS3 URA3::lexA-lacZ*) as shown in **Table 1**. The L40 strain can't grow in medium lacking the amino acids leu, trp and his. After transformation the yeast were grown in selective medium (SD) lacking the amino acids leu, trp and his. BRCA2-LexA or GALA4-TA-Rad51 transformed yeast were able to grow in medium containing His but lacking Trp or Leu respectively. Only yeast transformed with both vectors in which the fusion proteins interact was able to grow in SD media lacking the three amino acids (Leu, Trp and His)(7).


Table 1

Yeast Transformation	Growth	Growth Tested in SD-LTH agar plates: yeast nitrogen base without amino acids without Leu, Trp and His, supplemented with dextrose and 3-AT [*]
pBTM116-BRCA2 vector	Negative	
pPACT2-Rad51 vector	Negative	
pBTM116-BRCA2 + pPACT2 vectors	Negative	
pBTM116 + pPACT2-Rad51 vectors	Negative	
pBTM116-BRCA2+ pPACT2-Rad51 vectors	Positive	

^{*}3-AT, 3-Amino-Triazol is used to inhibit the basal expression of *His3* to avoid the growth of false positive yeast colonies.

C.2. Task #2 Screening of candidate compounds to inhibit BRCA2-RAD51 Interaction.

C.2.1.Primary Screening strategy




After transfection with the pBTM116-BRCA2 and the pPACT2-Rad51 vectors, the L40 yeast were plated on SD/-Leu/-Trp/-His/ (1mM 3-AT) to select for colonies, in which BRCA2 and RAD51 interact.

The clones were inoculated and grown to the mid-log phase in SD/-Leu/-Trp/-His/ (1mM 3-AT).

The cultures were diluted about 40 folds and transferred to each well (200 μ l) of the 96 well plate, containing has 2 μ l of a compound (1mg/ml) in 100% DMSO.

The plates were incubated overnight then read at 600nm in a microplatereader to determine the grow status.

96 well Plate format



(DMSO is the vehicle used to dissolve the compounds and Amphotericin B is an anti-yeast agent).

Using this format, the activity of 80 compounds can be obtained from one 96 well plate.

If a given compound inhibits the interaction between BRCA2 and Rad51, the growth of the yeast is inhibited due to the lack of His in the medium. The growth inhibition is calculated respect to the growth in the presence of vehicle (2 µl DMSO).

C.2.2.Primary screening results

The primary screening was carried out as described in C.2.1. with 14,080 compounds, and the final concentration of each compound was 10 µg/ml in SD/-Leu/-Trp/-His/ (1mM 3-AT) media.

The percentage of inhibition and the distribution rate of inhibition obtained are shown in **Table 2**.

Table 2. Inhibition rate

% of Inhibition	≥80	≥85	≥90	≥95
Hits	259	171	114	73
Hit rate	1.84%	1.21%	0.81%	0.52%

C.2.3. Secondary screening strategy

The compounds (Hits) that showed $\geq 80\%$ of inhibition of BRCA2 and RAD51 interaction during the primary screening (259 in total, **Table 2**) were chosen for further analyses. Sister cultures were grown in the presence of 10 $\mu\text{g/ml}$ of each compound plus SD/-Leu/-Trp/-His/ (1mM 3-AT) or SD/-Leu/-Trp. Inhibition of growth in the first medium (without Leu, Trp and His) indicated specific inhibition of BRCA2-Rad51 interaction while inhibition of growth in the second medium (without Leu and Trp) indicated toxicity.

From the 259 compounds, 130 have been already tested using the secondary screening, 20 of which showed selective growth inhibition in medium lacking Leu, Trp and His respect to the medium lacking Leu and Trp (**Table 3**).

Table 3. Inhibition rate comparison.

	SD/-LTH	SD/-LT(+His)
	Inhibition%	
1	91.2	23.3
2	80.6	36.0
3	88.6	44.1
4	84.8	52.1
5	80.1	19.5
6	80.1	33.8
7	80.8	-7.0
8	80.1	37.4
9	96.8	40.1
10	80.1	35.6
11	89.0	-3.0
12	91.7	27.6
13	96.8	30.9
14	89.6	-3.1
15	91.7	30.2
16	97.7	45.2
17	80.4	35.0
18	91.8	18.9
19	86.7	9.5
20	94.3	38.5

C.2.4 IC₅₀ value of inhibitor candidates

IC₅₀ determination was made for the 20 compounds that showed selectivity in the secondary screening. From a serial dilution of 10, 5, 2.5, 1.25, 0.625, 0.3125 and 0.156 $\mu\text{g/ml}$, 18 compounds were found to have IC₅₀ values less than 10 $\mu\text{g/ml}$ in SD/-Leu/-Trp/-His/ (1mM 3-AT) (**Table 3**).

Table 3. IC₅₀ value.

	SD/-LTH	SD/-LT(+his)	SD/-LTH
	%Inhibition		IC ₅₀ (µg/ml)
1	91.2	23.3	6.91
2	80.6	36.0	8.67
3	88.6	44.1	7.29
4	84.8	52.1	4.21
5	80.1	19.5	5.51
6	80.1	33.8	5.34
7	80.8	-7.0	3.33
8	80.1	37.4	2.06
9	96.8	40.1	2.88
10	80.1	35.6	>10
11	89.0	-3.0	>10
12	91.7	27.6	2.69
13	96.8	30.9	1.07
14	89.6	-3.1	3.77
15	91.7	30.2	2.46
16	97.7	45.2	2.53
17	80.4	35.0	4.27
18	91.8	18.9	8.09
19	86.7	9.5	6.84
20	94.3	38.5	6.90

In bold are indicated the best candidates to be tested to sensitize breast cancer cells to cisplatin as described in **TASK #3**

D.3 Task #3 Biological Evaluation of candidate inhibitors of BRCA2-Rad51 interaction

Biological effect of the candidate BRCA2-Rad51 inhibitory-compounds were tested in a panel of four well characterized sporadic breast cancer cell lines purchased from ATCC. The cell lines, MCF-7, T47D, Z75R, CAMA1 and NMDA231 express wild type BRCA2 and Rad51. We also include in the panel two commercially available BRCA2 deficient cell lines, CAPAN-1 as a negative control. The biological effect was determined using the NCI-SRB assay (7). Briefly, exponentially growing cells were plated in 96 well plates (2000 cells/well) in RPMI media containing 10% FBS and treated next day with cisplatin 0-40µM alone or in combination with 5µM of Compound 19. Five days later, the cells were fixed with cold TCA (10% final concentration), washed with water and incubated for half hour with the SRB reagent. After extensive washes with 0.1% acetic acid stained cells were lysed with 10mM Tris. The OD was measured using an Elisa-Plate reader at 450nm. The inhibitory dose ten, fifty and ninety (IC₁₀, IC₅₀ and IC₉₀) were obtained by logarithmic interpolation: $y = a \ln(x) + b$ where y is OD and x cisplatin concentration. The IC₁₀, IC₅₀ and IC₉₀ are defined as the x value corresponding to y equal 10, 50 or 90 respectively.

From the compound tested so far (five) only compound 19 (see Task# 2) was soluble in DMSO at a

concentration of DMSO which was not toxic to the cells (0.05%DMSO in culture media). The results obtained are summarized in **Table 4**

TABLE 4

		CAPAN-1	MCF-7	T47D	ZR75	CAMA1	NDA-MB231
Cisplatin Alone	IC ₅₀	0.87±0.1	1.78 ±0.07	23.36±2.06	3.83±0.82	5.23±1.17	3.12±0.034
	IC ₁₀	15.02±0.39	10.17±0.75	ND	ND	ND	ND
	IC ₉₀	0.048±0.01	0.30±0	0.84±0.13	0.16±0.049	0.28±0.84	0.10±0.021
Cisplatin + 5μM Comp19	IC ₅₀	0.78±0.41	1.73±0.11	19.47±3.43	3.2±0.2	4.43±0.06	<u>2.25±0.27*</u>
	IC ₁₀	10.25±1.09	9.00±0.3	ND	ND	ND	ND
	IC ₉₀	0.083±0.07	0.3±0.056	1.06±0.27	0.16±0.02	0.28±0.02	0.07±0.025

The values represent the mean value of 3 independent experiments for each cell line plus minus the standard deviation. ND indicates that the cisplatin concentration range was not high enough to reach the IC₁₀ value. Statistically significant difference between the mean values was assessed using the paired t-test for means. There was not significant differences between the sensitivity of the breast cancer cells to cisplatin alone vs. cisplatin compound 19 (5μM). The* indicate significant differences between means (p< 0.05).

Form the cell line panel tested, the only cell line sensitized to cisplatin by compound 19 was MDA-MB 231. As expected, the sensitivity to cisplatin of CAPAN-1 cells was not affected by compound 19. Interestingly MDA-MB231 cells are deficient for BRCA1 expression (8). Because it has been shown that BRCA1 is necessary for Rad51 related DNA repair process, it is possible that MDA-MB231 cells are more sensitive to the disruption of BRCA2-Rad51 interaction after DNA repair in the absence of functional BRCA1. We predict that compound 19 will sensitize MCF-7, T47D, ZR75 and CAMA1 cells at higher concentration (> 5μM), but the solubility of the compound is limiting. We are actually waiting for our collaborator Dr Jia Li at the Chinese National Center for Drug Screening to provide us with information regarding the structure of compound 19 to improve the solubility of the compound to be able to proceed with further biological and biochemical studies to confirm its effect on BRCA2-Rad51 interaction. We are also expecting to receive soon from him the additional 15 inhibitor candidates to test their effect on cisplatin sensitivity in our cell line panel.

D. KEY RESEARCH ACCOMPLISHMENTS

- We find 20 candidate inhibitors of the BRCA2-Rad51 interaction after screening of a library of 20,000 natural compounds interacting using a yeast 2 hybrid system.
- On of this compounds sensitize BRCA1 deficient cells to cisplatin.

E. REPORTABLE OUTCOMES There are not reportable outcomes associated with this research yet.

F. CONCLUSIONS. From the cell line panel tested, the only cell line sensitized to cisplatin by compound 19 was MDA-MB 231. As expected, the sensitivity to cisplatin of CAPAN-1 cells was not affected by compound 19. Interestingly MDA-MB231 cells are deficient for BRCA1 expression (8). Because it has been shown that BRCA1 is necessary for Rad51 related DNA repair process, it is possible that MDA-MB231 cells are more sensitive to the disruption of BRCA2-Rad51 interaction after cisplatin-induced DNA damage in the absence of functional BRCA1. We predict that compound 19 will sensitize MCF-7, T47D, ZR75 and CAMA1 cells at higher concentration ($> 5\mu\text{M}$), but the solubility of the compound is limiting. We are actually waiting for our collaborator Dr Jia Li at the Chinese National Center for Drug Screening to provide us with information regarding the structure of compound 19 to improve the solubility of the compound to be able to proceed with further biological and biochemical studies to confirm its effect on BRCA2-Rad51 interaction. We are also expecting to receive soon from him the additional 15 inhibitor candidates to test their effect on cisplatin sensitivity in our cell line panel.

G. REFERENCES

1. Mies L.G. Dronkert a, Roland Kanaar. Repair of DNA interstrand cross-links. *Mutation Research* 2001, 486:217–247.
2. Takata M, Sasaki MS, Tachiiri S, Fukushima T, Sonoda E, Schild D, Thompson LH, Takeda S. Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs. *Mol Cell Biol.*2001, 21:2858-2866.
3. Yuan SS, Lee SY, Chen G, Song M, Tomlinson GE, Lee EY. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. *Cancer Res.* 1999, 59: 3547-51.
4. Pellegrini,L., Yu,D.S., Lo,T., Anand,S., Lee,M., Blundell,T.L. andVenkitaraman,A.R. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. *Nature* 2002, 420, 287-293.
5. Xu ZY, Loignon M, Han FY, Panasci L, Aloyz R..Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis.*J Pharmacol Exp Ther.* 2005, 314:495-505.
6. Xu ZY, Loignon M, Han FY, Panasci L, Aloyz R. Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis. *J Pharmacol Exp Ther.* 2005 Aug;314(2):495-505.
7. Katagiri T, Saito H, Shinohara A, Ogawa H, Kamada N, Nakamura Y, Miki Y. Multiple possible sites of BRCA2 interacting with DNA repair protein RAD51. *Genes Chromosomes Cancer.* 1998 ;21:217-22.
8. Scully R, Xie A, Nagaraju G. Molecular functions of BRCA1 in the DNA damage response. *Cancer Biol Ther.* 2004 Jun;3(6):521-7.